<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01426191</url>
  </required_header>
  <id_info>
    <org_study_id>20090095</org_study_id>
    <nct_id>NCT01426191</nct_id>
  </id_info>
  <brief_title>Study on Cefotaxime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection</brief_title>
  <acronym>SWSB</acronym>
  <official_title>A Open Multi-center Clinical Study on Cefotaxime Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary Tract Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiangbei Welman Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xiangbei Welman Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the proposed study, the investigators plan to evaluate the efficacy and safety of
      Cefotaxime sodium and sulbactam sodium for injection (2:1)for the treatment of respiratory
      and urinary tract acute bacterial infection under the widely used in clinical conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cefotaxime is a third-generation cephalosporins.Cefotaxime sodium and sulbactam sodium for
      injection (2:1)plays a therapeutic role by the former inhibiting bacterial cell wall
      synthesis by irreversible competitive inhibition of β-lactamase.The antimicrobial effect of
      cefotaxime can be enhanced by the two combined.The compound specifically aims to the
      mechanism of bacterial resistance, extending the life of cefotaxime in the
      treatment-resistant pathogen infections.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>day0-day22-28</time_frame>
    <description>the incidence(%)of allergies, skin rashes, shock,death, etc.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Effect</measure>
    <time_frame>at weeks 4,day22-28</time_frame>
    <description>outcome:1.clinical cure 2. clinical failure population included patients who received the study drug, complied with the study protocol, did not have a missing or indeterminate clinical outcome response at the test-of-cure (TOC) visit, and had no confounding factors that interfered with the assessment of clinical outcome (e.g., use of nonstudy systemic antibiotic therapy on or after the first dose of the study drug for reasons other than treatment failure).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2032</enrollment>
  <condition>Respiratory Tract Infections</condition>
  <condition>Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>xinzhijun</arm_group_label>
    <description>1.5-3.0g,iv,bid or tid for 5-12 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>xinzhijun</intervention_name>
    <description>durg:Cefotaxime sodium and sulbactam sodium for injection(2:1)
1.5-3.0g,iv,bid or tid for 5-12 days;
Serious infections:1.0-1.5g,iv,tid or qid for 5-12 days</description>
    <arm_group_label>xinzhijun</arm_group_label>
    <other_name>Experimental</other_name>
    <other_name>shumate</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        hospitalized patients or outpatients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. patients who qualify for moderate and severe acute respiratory or urinary tract
             bacterial infection of acute bacterial infections need for systemic antibiotic
             therapy.

          2. Age&gt;18 years old, Gender: both

          3. Women of childbearing age were to be negative pregnancy test and agree to take
             contraceptive measures during the trial;

          4. patients were volunteers and signed informed consent form;

          5. patients did not participate in other clinical trials.

        Exclusion Criteria:

          1. Patients were hypersusceptibility to the test drug or other penicillins ,β-lactamase
             inhibitor

          2. Pregnant and Lactating women

          3. Patients have severe liver,kidney,cardiovascular,cerebrovascular,endocrine and
             hematopoietic system of primary diseases and that of immunodeficiency,advanced cancer
             or mental illness.

          4. Patients who were complicated by other diseases and thought to affect efficacy
             evaluations or poor compliance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>lanjuan lj li, docter</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>changqing cq li, doctor</last_name>
    <role>Study Director</role>
    <affiliation>Chongqing Red Cross Hospital</affiliation>
  </overall_official>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 23, 2011</study_first_submitted>
  <study_first_submitted_qc>August 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2011</study_first_posted>
  <results_first_submitted>July 2, 2019</results_first_submitted>
  <results_first_submitted_qc>September 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 4, 2019</results_first_posted>
  <last_update_submitted>September 11, 2019</last_update_submitted>
  <last_update_submitted_qc>September 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cefotaxime sulbactam sodium</keyword>
  <keyword>Phase IV clinical studies</keyword>
  <keyword>Respiratory and urinary tract infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>post market</recruitment_details>
      <pre_assignment_details>Third-generation cephalosporin resistant</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Xinzhijun</title>
          <description>1.5-3.0g,iv,bid or tid for 5-12 days
xinzhijun: durg:Cefotaxime sodium and sulbactam sodium for injection(2:1)
1.5-3.0g,iv,bid or tid for 5-12 days;
Serious infections:1.0-1.5g,iv,tid or qid for 5-12 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2032"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2032"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Xinzhijun</title>
          <description>xinzhijun:third generation beta-lactam cephalosporin and beta lactamase inhibitors (BLIs)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2032"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1982"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1250"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="782"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Chinese</title>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2032"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>the incidence(%)of allergies, skin rashes, shock,death, etc.</description>
        <time_frame>day0-day22-28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Xinzhijun</title>
            <description>1.5-3.0g,iv,bid or tid for 5-12 days
xinzhijun: durg:Cefotaxime sodium and sulbactam sodium for injection(2:1)
1.5-3.0g,iv,bid or tid for 5-12 days;
Serious infections:1.0-1.5g,iv,tid or qid for 5-12 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>the incidence(%)of allergies, skin rashes, shock,death, etc.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2032"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>nausea</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>vomiting</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>diarrhea</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pyrexia</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ALT increased</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>AST increased</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>no</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1962"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Effect</title>
        <description>outcome:1.clinical cure 2. clinical failure population included patients who received the study drug, complied with the study protocol, did not have a missing or indeterminate clinical outcome response at the test-of-cure (TOC) visit, and had no confounding factors that interfered with the assessment of clinical outcome (e.g., use of nonstudy systemic antibiotic therapy on or after the first dose of the study drug for reasons other than treatment failure).</description>
        <time_frame>at weeks 4,day22-28</time_frame>
        <population>included all the participants</population>
        <group_list>
          <group group_id="O1">
            <title>Xinzhijun</title>
            <description>1.5-3.0g,iv,bid or tid for 5-12 days
xinzhijun: durg:Cefotaxime sodium and sulbactam sodium for injection(2:1)
1.5-3.0g,iv,bid or tid for 5-12 days;
Serious infections:1.0-1.5g,iv,tid or qid for 5-12 days</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Effect</title>
          <description>outcome:1.clinical cure 2. clinical failure population included patients who received the study drug, complied with the study protocol, did not have a missing or indeterminate clinical outcome response at the test-of-cure (TOC) visit, and had no confounding factors that interfered with the assessment of clinical outcome (e.g., use of nonstudy systemic antibiotic therapy on or after the first dose of the study drug for reasons other than treatment failure).</description>
          <population>included all the participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2032"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>cure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2022"/>
                  </measurement_list>
                </category>
                <category>
                  <title>failure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Xinzhijun</title>
          <description>1.5-3.0g,iv,bid or tid for 5-12 days
xinzhijun: durg:Cefotaxime sodium and sulbactam sodium for injection(2:1)
1.5-3.0g,iv,bid or tid for 5-12 days;
Serious infections:1.0-1.5g,iv,tid or qid for 5-12 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2032"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2032"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="2032"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ALT increased</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="2032"/>
              </event>
              <event>
                <sub_title>AST increaesd</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="2032"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="2032"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2032"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="2032"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>pyrexia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="2032"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Directer of clinical trials</name_or_title>
      <organization>xiangbei welman pharmacuticol CO.,LTD</organization>
      <phone>020-38868707</phone>
      <email>gap@welman.com.cn</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

